UI Hospitals and Clinics
A Randomized, open-label, Phase 2 study of the IDO inhibitor INCB024360 versus tamoxifen for subjects with biochemical-recurrent-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer following complete remission with first-line chemotherapy
This study is being done to find out if the experimental drug INCB024360 is safe and has helpful effects when given to women with a certain type of ovarian cancer. Women who have elevated CA-125 (a marker in the blood used to track the disease) and no evidence of disease (¿biochemical recurrent only¿) after achieving complete remission with first-line chemotherapy will be asked to take part. This study will measure how long women who take INCB024360 survive without disease recurrence after study treatment, compared to those that take a hormonal therapy called tamoxifen. About 110 women with biochemical recurrent only ovarian cancer will be participating at approximately 35 study centers.
Sharon Stockman, (319) 356-2015
We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.